Web Desc
Antibody-Based Therapeutics for Cancer
Organizer(s): Louis M. Weiner and Paul Carter
Date: February 04 - 09, 2003
Location: Banff Centre, Banff, Alberta, Canada
Sponsored by Amgen Inc.
For important information on the coronavirus, please click here
Summary of Meeting:
Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected unconjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphomas. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new targets, including structurally-defined (e.g., through proteomic or genomic screening) and functionally-defined approaches. New approaches are needed to harness the ability of antibodies to initiate and sustain innate and adaptive immune responses. For immunoconjugate strategies to consistently succeed without undue host toxicity, new strategies must be developed to dissociate the process of antibody distribution from the effects of antibody-directed tumor targeting. This meeting will address these challenges in distinct sessions devoted to antibody structure and function, immunoconjugates, antibodies as tools for target discovery, antibodies as signaling agents and immune effectors, and in a session that highlights clinical advances in the field. Leaders in each of these areas will present their work and discussion periods will be used to highlight areas felt to have particular promise.
Discounted Abstract Deadline: October 3 2002
Discounted Registration Deadline: December 4 2002
We gratefully acknowledge additional support for this conference from:
Educational donation provided by AmgenJanssen Research & Development LLC
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA098899-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Tuesday, February 04 | 3:00PM - 7:00PM
Registration
Room: Max Bell Foyer


Tuesday, February 04 | 6:15PM - 7:15PM
Welcome
Room: Max Bell Foyer


Tuesday, February 04 | 7:15PM - 7:30PM
Orientation
Room: Max Bell Auditorium


Tuesday, February 04 | 7:30PM - 8:30PM
Keynote Address
Room: Max Bell Auditorium

Speaker 1 of 1
Sir Greg Winter, Trinity College Cambridge, UK
Evolution and the Antibody Binding Site

Wednesday, February 05 | 7:00AM - 8:00AM
Breakfast
Room: Donald Cameron Hall


Wednesday, February 05 | 8:00AM - 11:00AM
Antibody Structure and Function I
Room: Max Bell Auditorium

Speaker 1 of 5
* Paul Carter, Genentech, Inc., USA

Wednesday, February 05 | 8:00AM - 11:00AM
Antibody Structure and Function I
Room: Max Bell Auditorium

Speaker 2 of 5
Leonard Presta, DNAX Research Institute, USA
Engineering Therapeutic Antibodies for Improved Function

Wednesday, February 05 | 8:00AM - 11:00AM
Antibody Structure and Function I
Room: Max Bell Auditorium

Speaker 3 of 5
Raphael Clynes, Xencor, Inc., USA
Fc Receptors: Contributions to Antibody-Mediated Tumor Immunity

Wednesday, February 05 | 8:00AM - 11:00AM
Antibody Structure and Function I
Room: Max Bell Auditorium

Speaker 4 of 5
Peter J. Hudson, Avipep Pty Ltd, Australia
Design and Characterization of Multivalent Antibody Molecules

Wednesday, February 05 | 8:00AM - 11:00AM
Antibody Structure and Function I
Room: Max Bell Auditorium

Speaker 5 of 5
Andreas G. Plückthun, University of Zürich, Switzerland
Biophysical Properties of Antibody Fragments: Importance for Applications

Wednesday, February 05 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Wednesday, February 05 | 11:00AM - 1:00PM
Poster Setup
Room: Max Bell 252, 253


Wednesday, February 05 | 1:00PM - 10:00PM
Poster Viewing
Room: Max Bell 252, 253


Wednesday, February 05 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Foyer


Wednesday, February 05 | 5:00PM - 5:35PM
Antibody Structure and Function II
Room: Max Bell Auditorium

Speaker 1 of 1
Ian M. Tomlinson, GlaxoSmithKline, UK
Fully Human Domain Antibodies as Therapeutics

Wednesday, February 05 | 5:35PM - 7:00PM
Antibodies as Tools for Target Discovery
Room: Max Bell Auditorium

Speaker 1 of 2
* James D. Marks, University of California, San Francisco, USA
Tumor Cell Binding and Internalizing Antibodies from Phage Libraries

Wednesday, February 05 | 5:35PM - 7:00PM
Antibodies as Tools for Target Discovery
Room: Max Bell Auditorium

Speaker 2 of 2
Brian B. Haab, Van Andel Institute, USA
Analysis of Blood Proteins from Prostate and Pancreatic Cancer Patients using Antibody Microarrays

Wednesday, February 05 | 7:00PM - 8:00PM
Social Hour
Room: Max Bell 252, 253


Wednesday, February 05 | 8:00PM - 10:00PM
Poster Session 1
Room: Max Bell 252, 253


Thursday, February 06 | 7:00AM - 8:00AM
Breakfast
Room: Donald Cameron Hall


Thursday, February 06 | 8:00AM - 11:00AM
Immunoconjugates I
Room: Max Bell Auditorium

Speaker 1 of 4
Peter D. Senter, Seattle Genetics Inc., USA
Highly Potent Immunoconjugates for the Treatment of Cancer

Thursday, February 06 | 8:00AM - 11:00AM
Immunoconjugates I
Room: Max Bell Auditorium

Speaker 2 of 4
Ralph A. Reisfeld, The Scripps Research Institute, USA
Immunoctyokines for Cancer Immunotherapy

Thursday, February 06 | 8:00AM - 11:00AM
Immunoconjugates I
Room: Max Bell Auditorium

Speaker 3 of 4
* Richard H.J. Begent, University College London, UK
Antibody-Directed Enzyme Prodrug Therapy: Preclinical and Clinical Development with an Engineered Fusion Protein

Thursday, February 06 | 8:00AM - 11:00AM
Immunoconjugates I
Room: Max Bell Auditorium

Speaker 4 of 4
Carlos F. Barbas III, The Scripps Research Institute, USA
Chemical Approaches to Cancer Immunotherapy

Thursday, February 06 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Thursday, February 06 | 11:00AM - 1:00PM
Poster Setup
Room: Max Bell 252, 253


Thursday, February 06 | 1:00PM - 10:00PM
Poster Viewing
Room: Max Bell 252, 253


Thursday, February 06 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Foyer


Thursday, February 06 | 5:00PM - 7:00PM
Immunoconjugates II
Room: Max Bell Auditorium

Speaker 1 of 3
* Ellen S. Vitetta, University of Texas Southwestern Medical Center, USA
Engineering Toxins to Avoid VLS

Thursday, February 06 | 5:00PM - 7:00PM
Immunoconjugates II
Room: Max Bell Auditorium

Speaker 2 of 3
Richard J. Youle, NINDS, National Institutes of Health, USA
Targeting of Bcl-2 Family Proteins to Regulate Apoptosis

Thursday, February 06 | 5:00PM - 7:00PM
Immunoconjugates II
Room: Max Bell Auditorium

Speaker 3 of 3
Martin J. Glennie, University of Southampton, UK
Selecting CD20 Antibodies for Optimal Effector Function

Thursday, February 06 | 7:00PM - 8:00PM
Social Hour
Room: Max Bell 252, 253


Thursday, February 06 | 8:00PM - 10:00PM
Poster Session 2
Room: Max Bell 252, 253


Friday, February 07 | 7:00AM - 8:00AM
Breakfast
Room: Donald Cameron Hall


Friday, February 07 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Max Bell Auditorium

Speaker 1 of 4
* Hennie R. Hoogenboom, Ablynx, Belgium
Exploiting Phage Display Libraries for Cancer Diagnosis and Therapy

Friday, February 07 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Max Bell Auditorium

Speaker 2 of 4
Kathrin Tissot, MorphoSys AG, Germany
Intracellularly Stable Antibodies for Therapy and Target Validation

Friday, February 07 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Max Bell Auditorium

Speaker 3 of 4
Terence H. Rabbitts, MRC Laboratory of Molecular Biology, UK
Intracellular Antibody Capture (IAC): The Second Generation


Friday, February 07 | 8:00AM - 11:00AM
Advances in Antibody Engineering
Room: Max Bell Auditorium

Speaker 4 of 4
Quan Karen Zhu, Dana Farber Cancer Institute, USA
Intrabodies as Tools to Mediate Protein Function

Friday, February 07 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Friday, February 07 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Foyer


Friday, February 07 | 5:00PM - 7:00PM
Applications of Antibody Engineering
Room: Max Bell Auditorium

Speaker 1 of 3
Gregory P. Adams, Sesen Bio, USA
Targeting the Epidermal Growth Factor Receptor Family with Heterodimeric Single-Chain FV Molecules

Friday, February 07 | 5:00PM - 7:00PM
Applications of Antibody Engineering
Room: Max Bell Auditorium

Speaker 2 of 3
Jan van de Winkel, Genmab, Netherlands
Novel Antibody Therapeutics for Cancer

Friday, February 07 | 5:00PM - 7:00PM
Applications of Antibody Engineering
Room: Max Bell Auditorium

Speaker 3 of 3
* Anna M. Wu, University of California, Los Angeles, USA
Engineering Antibody Fragments for Targeting and Pharmacokinetic Properties

Friday, February 07 | 7:00PM - 8:00PM
Social Hour
Room: Foyer


Friday, February 07 | 8:00PM - 9:00PM
Workshop 1
Room: Max Bell Auditorium

Speaker 1 of 6
* Anna M. Wu, University of California, Los Angeles, USA

Friday, February 07 | 8:00PM - 9:00PM
Workshop 1
Room: Max Bell Auditorium

Speaker 2 of 6
Bryan Edwards, UK
Isolation of Agonistic Human Monoclonal Antibodies to TRAIL-R2 that Display Potent in vitro and in vivo Anti-Tumour Activities

Friday, February 07 | 8:00PM - 9:00PM
Workshop 1
Room: Max Bell Auditorium

Speaker 3 of 6
Mark S. Dennis, Denali Therapeutics, USA
Improved Tumor Targeting Using an Fab with a Prolonged Half-Life

Friday, February 07 | 8:00PM - 9:00PM
Workshop 1
Room: Max Bell Auditorium

Speaker 4 of 6
Marielle A. Otten, UMC-Utrecht, Netherlands
Immunoglobulin A Receptor (FcaRI) as Target for Antibody Immunotherapy

Friday, February 07 | 8:00PM - 9:00PM
Workshop 1
Room: Max Bell Auditorium

Speaker 5 of 6
Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Cell Line Engineering for Production of Therapeutic Antibody Glycoforms with Increased Biological Activity

Friday, February 07 | 8:00PM - 9:00PM
Workshop 1
Room: Max Bell Auditorium

Speaker 6 of 6
Robert M. Sharkey, Garden State Cancer Center, USA
Development of a Bispecific Antibody (bsMAb) Pretargeting System for the Treatment of CEA-Expressing Tumors: Clinical Studies to Define the Optimal Conditions for Delivering an 131I-Peptide

Saturday, February 08 | 7:00AM - 8:00AM
Breakfast
Room: Donald Cameron Hall


Saturday, February 08 | 8:00AM - 10:30AM
Antibodies as Effector Molecules
Room: Max Bell Auditorium

Speaker 1 of 3
Mark X. Sliwkowski, Genentech, Inc., USA
Therapeutic Approaches to Targeting ErbB2/HER2 in Solid Tumors

Saturday, February 08 | 8:00AM - 10:30AM
Antibodies as Effector Molecules
Room: Max Bell Auditorium

Speaker 2 of 3
* Louis M. Weiner, Georgetown University Medical Center, USA
Selective Manipulation of Immune Response Using Antibody-Based Fusion Proteins

Saturday, February 08 | 8:00AM - 10:30AM
Antibodies as Effector Molecules
Room: Max Bell Auditorium

Speaker 3 of 3
Dario Neri, ETH Zürich, Switzerland
Antibody-Promoted Tumor Blood Vessels Thrombosis

Saturday, February 08 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Saturday, February 08 | 4:30PM - 5:00PM
Coffee & Snacks Available
Room: Foyer


Saturday, February 08 | 5:00PM - 7:00PM
Clinical Updates
Room: Max Bell Auditorium

Speaker 1 of 4
Mark D. Pegram, Stanford Cancer Institute, USA
Antibodies Targeting HER2

Saturday, February 08 | 5:00PM - 7:00PM
Clinical Updates
Room: Max Bell Auditorium

Speaker 2 of 4
* George J. Weiner, University of Iowa, USA
Monoclonal Antibody Therapy of B Cell Lymphoma: What's Next?

Saturday, February 08 | 5:00PM - 7:00PM
Clinical Updates
Room: Max Bell Auditorium

Speaker 3 of 4
Gisela Schwab, Exelixis, Inc., USA
ABX-EGF, a Fully Anti-Epidermal Growth Factor Receptor (EGFr) Monoclonal Antibody (MAb)

Saturday, February 08 | 5:00PM - 7:00PM
Clinical Updates
Room: Max Bell Auditorium

Speaker 4 of 4
David A. Reardon, Duke University Medical Center, USA
Short Talk: Radiolabeled Anti-Tenascin Monoclonal Antibody 81C6 Administered into Surgical Resection Cavities in the Treatment of Patients with Malignant Brain Tumors

Saturday, February 08 | 7:30PM - 8:30PM
Social Hour
Room: Donald Cameron Hall


Saturday, February 08 | 8:30PM - 11:30PM
Entertainment
Room: Donald Cameron Hall


Saturday, February 08 | 8:30PM - 11:30PM
Cash Bar
Room: Donald Cameron Hall


Sunday, February 09 | 10:21AM - 10:21AM
Departure


*Session Chair
†Invited, not yet responded.